Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Meningioma

ClinicalTrials.gov lists 237 trials for Meningioma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 12.

MeSH D008579 Neoplasms Neoplasm C04 C10 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 43 Phase 1/2 Phase 1/2 15 Phase 2 Phase 2 63 Phase 3 Phase 3 10 Phase 4 Phase 4 3 Not applicable Not applicable 50 Observational Observational 52 Expanded access Expanded access 1 Phase 1 Phase 1 43 Phase 1/2 Phase 1/2 15 Phase 2 Phase 2 63 Phase 3 Phase 3 10 Phase 4 Phase 4 3 Not applicable Not applicable 50 Observational Observational 52 Expanded access Expanded access 1

Trials per phase (log scale)

237 of the 237 trials are tagged with Meningioma itself; the rest are tagged with a narrower condition beneath it.

Get the Meningioma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Meningioma trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 20

1992: 2 trials (Observational 1, Phase 3 1) 1994: 2 trials (Phase 1 2) 1996: 3 trials (Observational 1, Not applicable 1, Phase 1 1) 1997: 1 trials (Phase 1 1) 1998: 7 trials (Phase 2 4, Phase 1/2 1, Phase 1 2) 1999: 3 trials (Phase 3 1, Phase 2 1, Phase 1 1) 2000: 2 trials (Observational 1, Phase 1/2 1) 2001: 6 trials (Observational 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2002: 5 trials (Observational 1, Phase 3 1, Phase 1/2 1, Phase 1 2) 2003: 2 trials (Observational 1, Phase 2 1) 2004: 1 trials (Observational 1) 2005: 5 trials (Observational 1, Not applicable 1, Phase 2 1, Phase 1 2) 2006: 3 trials (Not applicable 2, Phase 2 1) 2007: 6 trials (Phase 3 1, Phase 2 4, Phase 1 1) 2008: 9 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 2, Phase 1 1) 2009: 5 trials (Observational 1, Phase 2 3, Phase 1 1) 2010: 10 trials (Not applicable 1, Phase 2 3, Phase 1/2 1, Phase 1 5) 2011: 4 trials (Observational 1, Not applicable 2, Phase 2 1) 2012: 5 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 1 2) 2013: 9 trials (Observational 2, Not applicable 2, Phase 2 2, Phase 1 3) 2014: 3 trials (Not applicable 2, Phase 1 1) 2015: 5 trials (Observational 1, Phase 2 3, Phase 1 1) 2016: 6 trials (Not applicable 1, Phase 2 3, Phase 1 2) 2017: 11 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 7, Phase 1 1) 2018: 8 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 2019: 13 trials (Observational 5, Not applicable 2, Phase 4 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2020: 14 trials (Observational 5, Not applicable 4, Phase 3 1, Phase 2 2, Phase 1 2) 2021: 9 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 2 2, Phase 1/2 1) 2022: 10 trials (Observational 2, Not applicable 6, Phase 2 1, Phase 1/2 1) 2023: 9 trials (Observational 2, Not applicable 5, Phase 1/2 1, Phase 1 1) 2024: 20 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 2 6, Phase 1/2 3, Phase 1 2) 2025: 16 trials (Observational 4, Not applicable 5, Phase 2 4, Phase 1/2 1, Phase 1 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 21
2025 16
2024 20
2023 9
2022 10
2021 9
2020 14
2019 13
2018 8
2017 11

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 25 trials starting in 2026 and about 23 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 39 trials still running at the 2026-10-09 snapshot; registered median of 49 months across 119 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Meningioma trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 43
Phase 1/2 15
Phase 2 63
Phase 3 10
Phase 4 3
Not applicable 50
Observational 52
Expanded access 1

How many Meningioma trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 13
Recruiting 62
Enrolling by invitation 1
Active, not recruiting 17
Available 1

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Meningioma trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 12
National Institutes of Health Clinical Center (CC) 3
SWOG Cancer Research Network 3

Which drugs are being tested for Meningioma? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
EVEROLIMUS 5
Cytoxan 4
Imatinib 4
PEMBROLIZUMAB 4
NIVOLUMAB 3

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Positron Emission Tomography (PET) 7
HU - Hydroxyurea 5
Bevacizumab 1 5
Lutetium-177 DOTATATE 4
SOC: Temozolomide 3

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Meningioma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Seizure 20 10
Fatigue 18 7
Headache 17 8
Vomiting 14 8
General disorders and administration site conditions - Other, specify: Disease Progression 13 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Meningioma? (140)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
[<sup>177</sup>Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2026 Yes
Neurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG). Radiation oncology (London, England) 2025 Yes
Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). Trials 2025 Yes
Phase 2 Trial of PD-1 Inhibitor Sintilimab in Recurrent/Progressive Meningioma. CNS neuroscience & therapeutics 2025 Yes
Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. Journal of clinical anesthesia 2024 Yes

Showing 5 of 140 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (9)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Meningioma Annual incidence 1-9 / 100 000 United States US Unspecified
Meningioma Annual incidence 1-9 / 100 000 United States US Exact
Meningioma Annual incidence 1-9 / 100 000 United States US Exact
Meningioma Annual incidence 1-9 / 100 000 Germany Not stated Exact
Meningioma Point prevalence Unknown Europe Not stated Exact

Showing 5 of 9 prevalence observations.

Start your 14-day trial Email me all 9 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Meningioma 2495 Exact Orphanet Rare Disease Ontology (ORDO)
Meningioma 2495 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages